Tyler Van Buren
Stock Analyst at TD Cowen
(2.46)
# 2,419
Out of 5,141 analysts
60
Total ratings
45.83%
Success rate
2.33%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $53.46 | -15.82% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.16 | - | 1 | Dec 2, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $11.23 | +33.57% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $34.79 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $30.39 | +31.62% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $68.14 | +39.42% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $151.40 | -17.44% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $31.98 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $57.63 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $16.20 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $15.48 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $32.34 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $49.87 | +20.31% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.68 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.93 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $779.67 | +53.91% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $21.37 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $35.58 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.21 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $64.11 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $68.39 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.46 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.75 | +113.74% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.42 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.99 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $31.58 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $11.60 | +1,839.66% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $6.80 | +12,767.65% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $15.78 | +153.49% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $19.66 | +52.59% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.24 | +3,932.26% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.13 | +1,308.45% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.04 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $34.22 | - | 1 | Aug 4, 2017 |
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $53.46
Upside: -15.82%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.16
Upside: -
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $11.23
Upside: +33.57%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $34.79
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $30.39
Upside: +31.62%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $68.14
Upside: +39.42%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $151.40
Upside: -17.44%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $31.98
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $57.63
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $16.20
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $15.48
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $32.34
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $49.87
Upside: +20.31%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $4.68
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.93
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $779.67
Upside: +53.91%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $21.37
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $35.58
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $43.21
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $64.11
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $68.39
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.46
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.75
Upside: +113.74%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.42
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.99
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $31.58
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $11.60
Upside: +1,839.66%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $6.80
Upside: +12,767.65%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $15.78
Upside: +153.49%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $19.66
Upside: +52.59%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.24
Upside: +3,932.26%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $2.13
Upside: +1,308.45%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $12.04
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $34.22
Upside: -